Biogen Inc. (BIIB) Bundle
A Brief History of Biogen Inc. (BIIB)
Company Overview
Biogen Inc. is a biotechnology company headquartered in Cambridge, Massachusetts. Founded in 1978, the company specializes in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases.
Financial Performance
| Financial Metric | 2023 Value |
|---|---|
| Total Revenue | $11.25 billion |
| Net Income | $3.02 billion |
| Research & Development Expenses | $2.87 billion |
| Stock Price (as of January 2024) | $275.63 |
Key Product Portfolio
- Tecfidera (multiple sclerosis)
- Spinraza (spinal muscular atrophy)
- Alzheimer's treatment Lecanemab (Leqembi)
- Hemophilia treatments
Major Achievements in 2023
Biogen received FDA approval for Leqembi, an Alzheimer's treatment, with Medicare coverage established in July 2023.
Research Focus Areas
- Neurological disorders
- Neurodegenerative diseases
- Immunology
- Rare genetic diseases
Corporate Structure
Publicly traded on NASDAQ under ticker BIIB, with a market capitalization of approximately $33.4 billion as of January 2024.
Strategic Partnerships
| Partner | Focus Area |
|---|---|
| Eisai Co., Ltd. | Alzheimer's treatment collaboration |
| Samsung Bioepis | Biosimilar development |
Employee Statistics
Total employees: 9,400 as of December 2023
Who Owns Biogen Inc. (BIIB)
Major Institutional Shareholders
| Shareholder | Shares Owned | Percentage |
|---|---|---|
| The Vanguard Group, Inc. | 13,777,978 | 13.02% |
| BlackRock Inc. | 11,370,317 | 10.75% |
| SSgA Funds Management, Inc. | 6,585,630 | 6.23% |
Top Institutional Owners
- Capital World Investors
- Primecap Management Company
- Fidelity Management & Research
Insider Ownership
Chris Mather, Chief Financial Officer, owns 45,231 shares.
Michel Vounatsos, Chief Executive Officer, owns 197,342 shares.
Ownership Distribution
| Category | Percentage |
|---|---|
| Institutional Investors | 83.4% |
| Insider Ownership | 0.6% |
| Retail Investors | 16% |
Biogen Inc. (BIIB) Mission Statement
Corporate Mission Overview
Biogen Inc. focuses on discovering, developing, and delivering innovative therapies for neurological and neurodegenerative diseases.
Strategic Focus Areas
- Multiple Sclerosis treatment
- Alzheimer's disease research
- Neurodegenerative disorder therapeutics
- Rare neurological conditions
Financial Performance Metrics
| Metric | 2023 Value |
|---|---|
| Total Revenue | $11.24 billion |
| Net Income | $3.61 billion |
| Research & Development Expenses | $2.87 billion |
| Market Capitalization | $36.8 billion |
Key Product Portfolio
| Product | Therapeutic Area | Annual Sales |
|---|---|---|
| TECFIDERA | Multiple Sclerosis | $3.2 billion |
| SPINRAZA | Spinal Muscular Atrophy | $1.7 billion |
| ADUHELM | Alzheimer's Disease | $302 million |
Research Pipeline
- 16 clinical-stage development programs
- 7 potential blockbuster therapies in advanced stages
- Focused on neuroscience and rare disease treatments
Global Presence
Operational Locations: United States, Switzerland, Denmark, Netherlands
Competitive Positioning
Ranked 4th globally in neuroscience pharmaceutical research and development.
How Biogen Inc. (BIIB) Works
Company Overview
Biogen Inc. is a biotechnology company headquartered in Cambridge, Massachusetts. Founded in 1978, the company focuses on discovering, developing, and delivering therapies for neurological and neurodegenerative diseases.
Financial Performance
| Metric | 2023 Value |
|---|---|
| Revenue | $10.8 billion |
| Net Income | $2.1 billion |
| Market Capitalization | $31.5 billion |
Key Product Portfolio
- Tecfidera (multiple sclerosis)
- Spinraza (spinal muscular atrophy)
- Aduhelm (Alzheimer's disease)
- Vumerity (multiple sclerosis)
Research and Development
Biogen invests $2.6 billion annually in research and development, with primary focus areas including:
- Neurology
- Neurodegenerative diseases
- Immunology
Global Presence
| Region | Number of Employees |
|---|---|
| United States | 7,400 |
| Europe | 2,100 |
| International Markets | 1,500 |
Stock Performance
As of January 2024, Biogen's stock (NASDAQ: BIIB) trades at approximately $280 per share.
How Biogen Inc. (BIIB) Makes Money
Revenue Streams
Biogen Inc. generates revenue primarily through the following product categories:
| Product Category | 2023 Revenue |
|---|---|
| Multiple Sclerosis Drugs | $4.17 billion |
| Alzheimer's Treatment (Lecanemab) | $795 million |
| Neuromuscular Therapies | $2.1 billion |
Key Products
- Tecfidera (multiple sclerosis): $2.4 billion in 2023
- Vumerity (multiple sclerosis): $436 million in 2023
- Spinraza (spinal muscular atrophy): $1.6 billion in 2023
- Aduhelm (Alzheimer's): $5 million in 2023
Financial Performance
Biogen's total revenue for 2023: $10.8 billion
| Financial Metric | 2023 Value |
|---|---|
| Net Income | $2.1 billion |
| Gross Margin | 81.7% |
| Research & Development Expenses | $2.6 billion |
Geographic Revenue Distribution
- United States: 84% of total revenue
- Europe: 12% of total revenue
- Rest of World: 4% of total revenue
Biogen Inc. (BIIB) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.